Stephenson Kirk A J, McKay Bryon R, Paton Katherine E
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.
J Curr Ophthalmol. 2024 Oct 16;36(1):103-106. doi: 10.4103/joco.joco_242_23. eCollection 2024 Jan-Mar.
To describe the first reported instance of an acute chorioretinal inflammatory response to cabozantinib.
Case report.
A 54-year-old Asian male presented with blurred vision 2 weeks following the commencement of cabozantinib for metastatic renal cell carcinoma. Ophthalmic examination revealed bilateral exudative retinal detachments and choroiditis in a pattern similar to Vogt-Koyanagi-Harada disease. Further investigations revealed latent tuberculosis (TB), and management of this ocular adverse event was with cabozantinib cessation, high-dose oral prednisone, single-agent anti-TB therapy, and methotrexate. Return of visual function and ocular anatomy occurred within 1 month.
Modern pharmacotherapy for metastatic cancer may increase survival, but a range of ocular and systemic adverse events are frequently seen. Screening and early intervention can mitigate adverse events and treatment burden, while maximizing benefits for this disadvantaged patient group.
描述首例报告的卡博替尼引起的急性脉络膜视网膜炎症反应。
病例报告。
一名54岁亚洲男性在开始使用卡博替尼治疗转移性肾细胞癌2周后出现视力模糊。眼科检查发现双侧渗出性视网膜脱离和脉络膜炎，其模式类似于Vogt-小柳原田病。进一步检查发现潜伏性结核病，该眼部不良事件的处理措施为停用卡博替尼、高剂量口服泼尼松、单药抗结核治疗和甲氨蝶呤。视力功能和眼部解剖结构在1个月内恢复。
转移性癌症的现代药物治疗可能会提高生存率，但经常会出现一系列眼部和全身不良事件。筛查和早期干预可以减轻不良事件和治疗负担，同时为这一弱势群体最大化获益。
